GSK repurchases 505,771 shares; treasury stake now 5.70% – 6-K
On 18 Jul 2025, GSK plc bought back 505,771 ordinary shares (nominal 31¼ p) through Merrill Lynch International as part of its previously announced non-discretionary buy-back programme.
Rhea-AI Filing Summary
On 18 Jul 2025, GSK plc bought back 505,771 ordinary shares (nominal 31¼ p) through Merrill Lynch International as part of its previously announced non-discretionary buy-back programme.
The shares were purchased between 1,319.0 p and 1,360.5 p, with a volume-weighted average price of 1,344.42 p. Since the programme commenced on 4 Jun 2025, GSK has repurchased 14,683,084 shares.
Following this latest transaction, the company now holds 232,817,467 shares in treasury, representing 5.70 % of total voting rights. Shares outstanding (excluding treasury) stand at 4,082,566,813, which investors should use as the denominator when assessing disclosure thresholds under the FCA’s DTR rules.
The filing contains no new earnings or guidance; it solely updates the market on the progress of GSK’s authorised share-repurchase programme.
Positive
- Continued execution of authorised share-buyback with 14.7 m shares repurchased since 4 Jun 2025, reflecting ongoing capital return commitment.
Negative
- None.
Insights
TL;DR – Routine buy-back update; modestly shareholder-friendly, limited valuation impact.
The purchase of 505.8k shares at a 1,344p VWAP marginally shrinks the float and signals continued cash allocation to shareholder returns. Treasury holdings now equal 5.7 % of voting rights, suggesting steady execution of the June-launched programme (14.7 m shares to date). Given GSK’s >£60 bn market cap, the incremental reduction (<0.02 % of shares) is too small to materially alter EPS or valuation in the near term. The disclosure is therefore neutral-to-slightly-positive for equity holders, reaffirming management’s commitment to capital return without altering fundamentals.
FAQ
AI-generated analysis. How Rhea-AI works. Not financial advice.
